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Abstract. In our previous studies, sulfatase 2 (Sulf2) was found
to upregulate vascular endothelial growth factor-D (VEGF-D)
expression in breast cancer. As VEGF-D plays an important role
in lymphangiogenesis, we hypothesized that Sulf2 facilitates
lymphangiogenesis in breast cancer by regulating VEGF-D.
To evaluate the functions of Sulf2 on lymphangiogenesis in
breast cancer, proliferation, apoptosis, cell cycle, cell mobility
and tube-formation of lymphatic endothelial cells (LECs) were
measured in vitro. Lymphangiogenesis in nude mouse ears and
breast cancer xenografts were examined in vivo. Furthermore,
the expression levels of related signaling pathway genes were
screened and verified in LECs. We found that Sulf2 significantly increased the mobility and tube formation of the LECs,
inhibited cisplatin-induced LEC apoptosis, but had no effect
on cell proliferation and the cell cycle. Moreover, recombinant
Sulf2 (rSulf2) combined with VEGF-D further promoted
the proliferation, cell cycle, mobility and tube-like structure formation in the LECs, and at the same time inhibited
cisplatin-induced apoptosis especially in the late stage. Sulf2
also significantly increased the density of lymphatic vessels
in mouse ears and breast cancer xenografts in vivo. AKT1
was also shown to be upregulated and activated by Sulf2. Our
results confirmed that Sulf2 facilitated lymphangiogenesis
in breast cancer cells by regulating VEGF-D and that the
AKT1‑related signaling pathway was involved.
Introduction
Extracellular sulfatases, especially heparan endosulfatases (Sulfs), play important roles in cancer progression by
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modifying the sulfate patterns of heparan sulfate proteoglycans (HSPGs) located on the surface of most animal
cells (1-3). HSPGs can be released into the extracellular matrix
and can also be detected in serum. HSPGs carry out many
structural and signaling functions through binding to protein
ligands (4,5). The Sulf family includes two structurally similar
endogenous sulfatases (Sulf1 and Sulf2) with 64% homology
in highly conserved heparin-binding domains, but with
different functions (2-4). Sulfatase 2 (Sulf2) is an extracellular endoglucosamine‑6-sulfatase and considered as a bona
fide cancer-causing agent in multiple types of cancer (6,7).
Sulf2 is overexpressed in many tumor cells and was shown
to promote tumorigenesis in many human cancers such as
hepatocellular (8), pancreatic (9), ovarian (10), breast (6,10),
and non-small cell lung carcinoma (11). Sulf2 also increased
the activities of growth factors such as vascular endothelial
growth factor (VEGF) and fibroblast growth factor-1 (FGF‑1),
and certain chemokines such as stromal cell-derived
factor-1 (SDF-1) and secondary lymphoid-tissue chemokine (SLC), stimulating the biological functions of endothelial
cells to promote angiogenesis (5,12). Although Sulf2 was
confirmed to facilitate angiogenesis, the effect of Sulf2 on
lymphangiogenesis in tumors is still unknown.
Lymphangiogenesis, which is the formation of new
lymphatic vessels, is a common process in normal tissue
development, inflammation, wound healing and lymphatic
edema (13,14). Recently, more and more research has found
lymphangiogenesis to play an important role in tumor
progression and metastasis (15,16). New lymphatic vessels are
composed of one single layer of lymphatic endothelial cells. The
basement membranes of new lymphatic vessels are incomplete,
and the endothelial cells do not connect tightly. These factors
allow tumor cells to easily invade new lymphatic vessels and
metastasize to regional lymph nodes or distant organs (15-18).
In recent years more research oncologists are becoming interested in the mechanisms of tumor-induced lymphangiogenesis
in various tumors (19,20). Breast cancer is one of the most
common types of cancer among women worldwide (21,22).
Over 50% of early-stage breast cancer patients have local
lymph node metastasis (18). Moreover, regional lymph node
metastasis in breast cancer is also one of the main factors that
leads to breast cancer metastasis and poor prognosis (23,24).
Tumor size and regional lymph node metastasis are used as
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biological indicators for breast cancer classification and selection markers for treatment strategies. Vascular endothelial
growth factor-C (VEGF-C) and VEGF-D could combine with
vascular endothelial growth factor receptor-3 (VEGFR-3)
to induce lymphangiogenesis (20,25,26). Our previous
studies also suggested that breast cancer patients with high
VEGF-D expression would have more regional lymph node
metastasis, poor disease-free survival (DFS) and poor overall
survival (OS) (20,25). Karpanen et al (24) demonstrated that
when VEGF-D-overexpressing cells were implanted into
transgenic mice, tumor-associated lymphangiogenesis was
induced in several orthotopic mouse models.
Previously, we demonstrated that VEGF-D/FIGF, a
member of the VEGF family, was upregulated by Sulf2 (6). In
this study, we hypothesized that Sulf2 facilitates lymphangiogenesis in breast cancer by regulating VEGF-D. To evaluate
the functions of Sulf2 in lymphangiogenesis in breast cancer,
we examined the proliferation, apoptosis, cell cycle, mobility
and tube-like structure formation of LECs in vitro, as well
as lymphangiogenesis in mouse ears and xenografts in vivo.
The expression of related signaling pathway genes was also
screened and verified in LECs.
Materials and methods
Cell lines. Human breast cancer cell lines (MCF-7,
MDA-MB‑231) were purchased from the The Cell Bank
of the Chinese Academy of Sciences (Shanghai, China).
HEK293T cells used for lentivirus packaging were stocked
in our own laboratory. All cells were cultured in Dulbecco's
modified Eagle's medium (DMEM; HyClone Laboratories,
Inc., Logan, UT, USA) with 10% fetal bovine serum (FBS)
and penicillin‑streptomycin (all from Gibco, Grand Island,
NY, USA). LECs were cultured in Endothelial Cell Growth
Medium (ECGM) (both from PromoCell, Heidelberg,
Germany). All cells were cultured at 37˚C in 5% CO2.
Conditioned medium (CM) collection. CM was collected from
the supernatant of MCF-7 cells. MCF-7 cells release high
levels of Sulf2 protein in the supernatant which was confirmed
in our previous study (6). The MCF-7 cells were cultured in
DMEM until 80% confluence and were subsequently cultured
in OptiMEM (HyClone Laboratories, Inc.) for another 72 h.
The supernatant was collected and concentrated using Amicon
Ultra filters 30 D (Millipore, Billerica, MA, USA) and then
was kept in 50 mM HEPES buffer (pH 8.0; Biochrom GmbH,
Berlin, Germany) for further study.
Flag-Sulf2 vector construct. The signal peptide sequence of
Sulf2 was removed. The new peptide sequences of signal Flag
and Ig-k were added with three rounds of PCR using three
forward primers (Table I) and reverse primer 5'-CGG
GATCCTTAACCTTCCCAGCCTTCCC-3'. The PCR conditions were 95˚C for 5 min, followed by 35 cycles of
amplification, 95˚C for 15 sec, 55˚C for 15 sec and 72˚C for
1 min. The PCR sequence structures of flag-Sulf2 were signal
peptide, signal peptide cleavage site, Flag, the linker portion of
GSG and the Sulf2 cDNA sequence (Table Ⅱ). The amplified
fragment was cloned into the pCDH (System Biosciences,
Mountain View, CA, USA) to form the pCDH‑Flag-Sulf2

vector construct. The sequences of the positive clone were
identified using enzyme digestion and gene sequencing detection (Shanghai Meiji, Shanghai, China).
rSulf2 combination and purification. The pCDH‑Flag‑Sulf2
lentivir us was packaged in HEK293F cells using
Lipofectamine 2000 (Invitrogen Life Technologies, Carlsbad,
CA, USA) according to the manufacturer's instructions. The
supernatant from the lentivirus-transfected HEK293F cells
was collected and incubated with anti-Flag/M2 agarose
beads (Sigma‑Aldrich, St. Louis, MO, USA) at 4˚C overnight. The beads were washed three times with washing
buffer. The bound proteins were eluted with 0.1 mg/ml
Flag peptide (DYKDDDDK). The eluate was concentrated
though Amicon Ultra filters 30 D and kept in 50 mM HEPES
buffer (pH 8.0).
qRT-PCR analysis. Total RNA was isolated from cells using
TRIzol reagent and reverse transcribed into cDNA using
SuperScript III Reverse Transcriptase (both from Invitrogen
Madison, WI, USA). The mRNA level was determined
using the 7900HT qRT-PCR system (Applied Biosystems,
Foster City, CA, USA) using SYBR® Green Real-time PCR
Master Mix (Takara, Shiga, Japan). Primers for qRT-PCR
are listed in Table Ⅲ. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control. Relative
mRNA levels were calculated using the ΔΔCt method.
Western blot (WB) analysis. Cells were harvested in the presence of a protease inhibitor cocktail (Sigma-Aldrich) in RIPA
lysis buffer (Beyotime, Jiangsu, China). Equal amounts of
proteins from the cells were resolved on SDS-PAGE and then
transferred onto PVDF membranes as previously described (6).
The membranes were separately probed with rabbit anti‑FIGF
(1:1,000, PAB4879; Abnova, Atlanta, GA, USA), rabbit
anti‑AKT1 (1:1,000, ab32505), rabbit anti-pAKT1 (s473)
(1:1,000, ab66138; both from Abcam, Cambridge MA, USA),
rabbit anti-mouse LYVE-1 (1:1,000, ab36993; AngioΒio, San
Diego, CA, USA), rabbit anti-GAPDH (1:500; Sigma-Aldrich)
for 1 h. Subsequently, the membranes were washed with
TBST, and then incubated with goat anti‑rabbit HRP (1:500;
Sigma‑Aldrich) for 1 h. Bound antibody chemiluminescence
was detected using chemiluminescence kits (Thermo Fisher
Scientific, Darmstadt, Germany). The optical density was
determined using a scanning densitometer and analyzed using
Quantity One software (Bio-Rad, Hercules, CA, USA).
Proliferation assay. LECs were divided into four groups
(control-1, rSulf2, VEGF-D, rSulf2+VEGF-D). Control-1 was
cultured with only DMEM media. The other groups were separately cultured with rSulf2, VEGF-D and rSulf2+VEGF‑D.
The final concentration of rSulf2 and VEGF-D in each group
was 50 ng/ml. The proliferation of LECs was assessed by
the MTT method. Cells were dissociated from cell flasks
by trypsin (Sigma-Aldrich) digestion and were seeded into
96-well plates (1x105 cells/ml). The proliferation of LECs in
the four groups was detected at different time-points (0, 12,
24, 36 and 48 h). All cells were incubated at 37˚C for 4 h
followed by the addition of 10 µl MTT (5 mg/ml) and 100 µl
DMSO. The absorbance value of each well was measured
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Table I. Upstream primers of flag-Sulf2.
No.
Flag-Sulf2 F1
Flag-Sulf2 F2
Flag-Sulf2 F3(Nhe I)

Primer sequences
5'-GACGATTACAAGGATGACGACGATAAGGGTTCTGGCTTCCTGTCGCACCACCGC-3'
5'-TGGGTACTGCTGCTCTGGGTTCCAGGTTCCACTGGTGACGATTACAAGGATGACGACG-3'
5'-CTAGCTAGCATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGG-3'

Table II. DNA sequences and amino acid sequences of flag-Sulf2.
Genes

DNA sequence

Signal peptide

ATGGAGACAGACACACTCCTGCTATGGGTA
CTGCTGCTCTGGGTTCCAGGTTCCACTGGT
Cleavage site
GAC
Flag
GATTACAAGGATGACGACGATAAG
Linker
GGTTCTGGC
Sulf2
TTCCTGTCGCACCACCGCCTGAAA…
(Sulf2 full length...)
		

Amino acid sequence
METDTLLLWVL
LLWVPGST
D
DYKDDDDK
GSG
FLSHHRLK...
(Sulf2 full length
amino acid chain...)

Table Ⅲ. Real-time PCR primers.
Gene
GAPDH (HUMAN)
PLA2G1B
PLA2G5
PLA2G6
PLA2G2D
AKT1
PIK3R1
PIK3R3

Primer sequences
F
R
F
R
F
R
F
R
F
R
F
R
F
R
F
R

5'-GGGAAACTGTGGCGTGAT-3'
5'-GAGTGGGTGTCGCTGTTGA-3'
5'-TGTGGCAGTTCCGCAAAAT-3'
5'-GCAGCCGTAGTTGTTGTATTCC-3'
5'-AACCCCAGAGATGAAAGGC-3'
5'-CGTAGTTTGTCAGGGCGTTC-3'
5'-CCACATCATCCCTTCTCCCT-3'
5'-CTTTCACTCCTCCTCCATCCA-3'
5'-GGCCTAGAGTGGCAAATGG-3'
5'-GGGAAAACAGGGGAAACAGA-3'
5'-GCCCTGCTACCTGTTCTTGG-3'
5'-AAGCAAATGGCAAAGTGTGAG-3'
5'-TTGGAAGCAGCAACCGAAAC-3'
5'-CTTCGCCGTCCACCACTACA-3'
5'-TGGTTCAGCACAACGACTCC-3'
5'-CACCTCTCTTCCCACTTCCT-3'

Length (bp)
299
77
134
181
104
266
123
99

F, forward; R, reverse.

using a microplate reader (Bio-Tek, Winooski, VT, USA) at a
wavelength of 570 nm.
Apoptosis assay. The aforementioned four groups were
used. Apoptosis was determined by dual staining using
Annexin V/FITC and propidium iodide (Invitrogen). Briefly,
the log phase of LECs was seeded into 24-well cell culture
plates (1x105 cells/well). Subsequently, LECs were treated

with 10 µg/ml cisplatin (Qilu Pharmaceutical Co., Shanghai,
China) for 24 h and then dissociated from the wells with
0.25% trypsin, spun at 1,500 rpm for 5 min, resuspended
in Annexin V binding buffer, stained with 1 µl Annexin V/
FITC for 15 min and 1 µl propidium iodide for 1 min. The
cells were analyzed using the FACSCalibur System (BD
Biosciences, San Jose, CA, USA). The relative proportion of
Annexin V-positive cells, representing apoptotic cells, was
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determined using FlowJo software (FlowJo, LLC, Ashland,
OR, USA).
Cell cycle assay. The aforementioned four groups were used.
The cell cycle distribution of LECs was determined by propidium iodide staining and flow cytometric analysis. After LECs
were treated with 10 µg/ml cisplatin for 24 h, the cells were
dissociated from the wells with 0.25% trypsin. Subsequently,
they were fixed in 70% ethanol overnight at -20˚C and incubated in RNase A at 37˚C for 30 min. Propidium iodide was
then added and the cells were incubated in a dark room for
30 min. Flow cytometry was used to detect the cell cycle
distribution. The proliferation index (PI) was calculated using
the formula PI = (S + G2)/(S + G1 + G2) x 100%.
LEC mobility assay. The aforementioned four groups were
used. The mobility of LECs was determined in 12-well
Boyden chamber plates and polycarbonate membrane filter
inserts (CoStar Group, Inc., Washington, DC, USA) with
8-µm pores. For the cell mobility assay, the interior of the
Transwell insert was coated with Matrigel (BD Pharmingen,
San Diego, CA, USA), which mimics the basement membrane.
In all, 1x105 cells were seeded into the upper chamber. The cell
suspension was also seeded onto the membrane in the upper
chamber and the lower chamber was filled with 1 ml medium
with 10% FBS. After 48 h, the non-migrating cells on the
surface of the upper chamber were removed with cotton swabs.
The migrating cells at the bottom of the membrane were fixed
in formaldehyde for 1 min and then stained with crystal violet.
The stained membranes were cut and placed onto a glass slide
and the number of invading cells at the bottom surface of the
membrane was counted three times under a bright-field light
microscope.
Lymphatic tube-like structure formation assay. The aforementioned four groups were used. The lymphangiogenic capacities
of LECs on Matrigel were determined according to the manufacturer's instructions. The Matrigel was melted in 4˚C and
was diluted to half its concentration by media and then was
added into 24-well plates for cooling down. The 24-well plates
were placed in an incubator for 30 min to solidify the glue.
LECs (5x105) were digested and added into each well before
this solidification process. The numbers of new lymphatic
tubes were detected using an inverted phase contrast microscope (AMG, Bovenden, Germany) after 24 h of culture.
Lymphangiogenesis in mouse ears. Four-week-old, BALB/
c-nu mice (weight, 15 g) were purchased from the Shanghai
Experimental Animal Center of the Chinese Academy of
Sciences (Shanghai, China). The mice were divided into
three groups (control-2, CM-nu, rSulf2-nu). A total of 0.1 ml
0.9% saline, CM (50 mM) and rSulf2 (50 mM) were separately injected into the root of the mouse ears every day for
six weeks. Excised mouse ears were fixed in formalin buffer
and embedded in paraffin for advanced testing. All experimental protocols followed the instructions of the Chinese
Council on Animal Care and were approved by the Animal
Experimental Ethical Inspection of Shanghai Ninth People's
Hospital affiliated to Shanghai Jiaotong University, School of
Medicine [permit (no. 20015) 25].

Figure 1. Growth curve of lymphatic endothelial cells (LECs) at different
time-points. Cell growth curves were drawn based on the absorbance value
of live cells at different time-points. Compared with the control-1, LECs
treated with recombinant Sulf2 (rSulf2) or vascular endothelial growth
factor-D (VEGF-D) showed higher cell proliferation after 48 h, but the difference was not significant. However, the rSulf2+VEGF-D group showed
significantly higher cell proliferation than control-1 at 48 and 60 h, *P<0.05.

Lymphangiogenesis in breast cancer xenografts. Six-week-old,
18-g female Nod/scid mice were purchased from Shanghai
Experimental Animal Center of the Chinese Academy of
Sciences. MDA-MB-231 breast cancer cells were detached with
0.25% trypsin and resuspended in HBSS/Matrigel (1:1 volume)
to 10 7 cells/ml. Xenografts were generated by injecting
0.2 ml cell suspension into the area of the mammary fat pad.
Mice were divided into three groups (control-3, CM-scid,
rSulf2‑scid). A total of 0.1 ml 0.9% saline, CM (50 mM) and
rSulf2 (50 mM) were separately injected into xenografts every
day until 6 weeks. Excised xenografts were fixed in formalin
buffer and embedded in paraffin for advanced testing. All
experimental protocols followed the instructions of the
Chinese Council on Animal Care and were approved by the
Animal Experimental Ethical Inspection of Shanghai Ninth
People's Hospital affiliated to Shanghai Jiaotong University,
School of Medicine [permit (no. 20015) 25].
Immunohistochemistry (IHC). Five-micron-thick sections of
the paraffin-embedded tissues were deparaffinized in xylenes
and rehydrated through a graded alcohol series. Heat-induced
epitope retrieval (HIER) was performed by immersion of the
tissue sections in 8 mM EDTA buffer (pH 8.0) for 20 min
at 98˚C. IHC staining was performed using a horseradish
peroxidase-labeled polymer K4001 (Dako, Zagreb, Croatia)
according to the manufacturer's instructions. Briefly, the
slides were incubated with 3% hydrogen peroxide and
1% bovine serum albumin (BSA; Sigma-Aldrich) for 10 min
each. To visualize lymphatic vessels, the sections were
exposed to the primary antibody, rabbit anti-mouse LYVE-1
which was diluted as recommended in 3% BSA, for 1 h at
room temperature. The slides were then incubated with goat
anti-rabbit HRP for 30 min followed by incubation with the
DAB chromogen (Dako) for 5 min. Finally, the slides were
counterstained with hematoxylin (Thermo Fisher Scientific,
Waltham, MA, USA), blued in 1% ammonium hydroxide,

ONCOLOGY REPORTS 36: 3161-3171, 2016

3165

Figure 2. The apoptosis of lymphatic endothelial cells (LECs) detected by flow cytometry. (A) Annexin V/propidium iodide-labeled apoptotic LECs were
detected using flow cytometry. (B) The effects of recombinant Sulf2 (rSulf2), vascular endothelial growth factor-D (VEGF-D) and rSulf2+VEGF-D on LEC
apoptosis. *P<0.05, **P<0.01.

dehydrated, and mounted with Acrymount. Consecutive
sections where the primary antibody was omitted were used
as negative controls. The washing buffer used was 1X TBS
with 0.05% Tween-20 (Thermo Fisher Scientific).

Results

the control-1, the rSulf2 and VEGF-D groups showed higher
cell growth after 36 h, but the difference was not significant.
However, the group treated with rSulf2+VEGF-D showed
a significant difference in the absorbance of live cells at
48 and 60 h (0.36±0.03 vs. 0.24±0.01, 0.41±0.02 vs. 0.25±0.01
respectively, P<0.05, Fig. 1). The results indicated that Sulf2
or VEGF-D could enhance LEC proliferation, but their effects
were not significant. Furthermore, LECs treated with rSulf2
and VEGF‑D showed a significantly higher growth rate than
the cells treated with control-1. Collectively, these data indicated that Sulf2 could promote breast cancer proliferation
through the activation of VEGF-D.

Sulf2 with VEGF-D promotes LEC proliferation. To evaluate
the role of Sulf2 in LEC proliferation, an MTT assay was used
to detect the proliferation of LECs at different time-points.
Cell growth curves were drawn based on the absorbance
value of live cells at different time-points. Compared with

Sulf2 inhibits cisplatin-induced LEC apoptosis. To evaluate
the role of Sulf2 in LEC apoptosis, we measured the
cisplatin-induced apoptosis and necrosis of LECs by flow
cytometry. Compared with the control-1, treatment with
rSulf2 resulted in a significant increase in the percentage of

Statistical analysis. Data are presented as the mean ± standard
deviation (SD) of at least three independent experiments with
three or more replicates. Continuous data were analyzed using
a two-tailed Student's t-test. P<0.05 was considered to indicate
a significant difference.
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Figure 3. Cell cycle distribution of lymphatic endothelial cells (LECs) as detected by flow cytometry. (A) Cell cycle distribution in the LECs was detected
using flow cytometry, and the abscissa indicated the amount of DNA. The G1, S and G2/M phases are marked. (B) Effects of recombinant Sulf2 (rSulf2),
vascular endothelial growth factor‑D (VEGF-D) and rSulf2+VEGF-D on the cell cycle of LECs. *P<0.05.

live cells (86.98±3.84 vs. 67.60±2.12, P<0.05) and a significant
decrease in total apoptosis (9.75±4.03 vs. 17.95±0.78, P<0.05).
A closer look at the different stages in apoptosis revealed
that the most significant difference occured in the late stage
(4.95±2.19 vs. 14.3±1.27, P<0.05) instead of the early stage
(4.80±1.83 vs. 3.65±2.05, P>0.05). Treatment with VEGF-D
caused a significant decrease in the percentage of dead cells
(3.35±1.48 vs. 14.5±1.27, P<0.05), but had no significant effects
on the percentage of live cells (86.75±4.31 vs. 67.6±2.12,
P>0.05) and total apoptosis (9.85±5.72 vs. 17.95±0.78,
P>0.05). Treatment with rSulf2+VEGF-D resulted in
a significant increase in the percentage of live cells
(87.11±1.27 vs. 67.60±2.12, P<0.01) and a more significant
decrease in total apoptosis (10.81±2.40 vs. 17.95±0.78, P<0.05)
and percentage of dead cells (2.05±0.64 vs. 14.50±1.27,
P<0.01), especially in the late stage (7.31±1.56 vs. 14.31±1.27,
P<0.05) (Fig. 2A and B). The results showed that VEGF-D
had no direct effect on cisplatin‑induced LEC apoptosis.
The rSulf2- and rSulf2+VEGF-D-treated groups showed a
significant increase in the percentage of live cells, decreased

cell necrosis and inhibited cisplatin‑induced LEC apoptosis,
particularly in the late stage of apoptosis. However,
rSulf2+VEGF-D treatment had a greater effect on apoptosis.
Based on these results, rSulf2 inhibited the apoptosis of LECs
by activating VEGF-D.
Sulf2 with VEGF-D improves cell cycle distibution of
cisplatin-pretreated LECs. To ascertain the role of Sulf2 in
the cell cycle control of LECs, the cell cycle distribution of
LECs was assessed by flow cytometry. Compared with the
control-1, rSulf2 treatment caused no difference in the number
of cells in the G1 phase (78.70±6.40 vs. 81.75±4.55, P>0.05),
the S phase (6.99±2.42 vs. 6.31±1.08, P>0.05) and the G2/M
phase (14.45±4.45 vs. 11.99±3.61, P>0.05). Moreover, it had
no effect on the PI index (21.41±6.76 vs. 18.29±4.65, P>0.05).
Furthermore, VEGF-D treatment had no significant effect on
the PI index (24.55±3.23 vs. 18.29±4.65, P>0.05), the number
of cells in the G1 phase (75.23±5.03 vs. 81.75±4.55, P>0.05),
the S phase (11.9±1.5 vs. 6.31±1.08, P>0.05) and the G2/M
phase (12.56±3.26 vs. 11.99±3.61, P>0.05). rSulf2+VEGF‑D
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Figure 4. Lymphatic endothelial cell (LEC) mobility assay using a Transwell chamber. (A) LECs migrated to the lower side of the chamber membranes after
being incubated for 48 h. (B) The number of LECs that migrated though the chamber membranes. *P<0.05.

treatment caused a significant decrease in the number of
cells in the G1 phase (74.3±5.10 vs. 81.75±4.55, P<0.05), the
S phase (8.32±1.02 vs. 6.31±1.08, P<0.05) and the G2/M
phase (16.95±3.55 vs. 11.99±3.61, P<0.05) as well as a
significantly higher PI index (25.37±2.50 vs. 18.29±4.65,
P<0.05). We concluded that Sulf2 together with VEGF-D
significantly promoted cell cycle progression from the G1
phase to the G2/M phase and increased the PI index in the
LECs (Fig. 3A and B), while Sulf2 or VEGF-D alone had no
significant effect on the cell cycle of the LECs.
Sulf2 promotes breast cancer migration. Compared with
the control-1, the rSulf2- or VEGF-D-treated LECs showed
higher migration through the membrane of the Boyden

Figure 5. The effect of recombinant Sulf2 (rSulf2) in an in vitro lymphatic
tube formation assay. Compared with control-1, treatment with rSulf2, vascular endothelial growth factor-D (VEGF-D) and rSulf2+VEGF-D resulted
in a significant increase in the number of new lymphatic tubes formed, especially in the rSulf2+VEGF-D group.
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Figure 6. Lymphatic vessels in nude mouse ears detected by immunohistochemical staining. (A) Immunohistochemical staining showing the number of
lymphatic vessels in nude mouse ears are indicated by the red arrows. (B) Quantification of the number of lymphatic vessels in the three groups, *P<0.05.

chamber (163.33±20.98, 155.67±10.96 vs. 90.0±12.52,
P<0.05). Moreover, the rSulf2+VEGF-D treated cells showed
the highest migration rate (247.33±23.07 vs. 90.0±12.52,
P<0.05) (Fig. 4A and B). These observations clearly suggested
that rSulf2 or VEGF-D enhanced LEC migration, but rSulf2
with VEGF-D might work synergistically.
Sulf2 promotes lymphatic tube-like structure formation
in vitro. To examine the effect of Sulf2 on lymphatic tube‑like
structure formation of LECs in vitro, LECs were seeded
on Matrigel substrate. Compared with the control-1, more
lymphatic tube-like structures were formed by LECs treated
with rSulf2, VEGF-D, and rSulf2+VEGF-D, after 24 h (Fig. 5).
The results showed that rSulf2 or VEGF-D increased lymphatic
tube-like structure formation of the LECs, however, the effect
of Sulf2 with VEGF-D was more significant, suggesting that
Sulf2 could promote lymphangiogenesis in vitro through the
activation of VEGF-D.
Sulf2 improves lymphangiogenesis in nude mouse ears. The
nude mouse ears were examined by pathological sections.

The lymphatic vessels were detected using IHC. Compared
with the control-2, the CM-nu and rSulf2-nu groups showed
significantly more lymphatic vessels (6.8±1.48 vs. 1.6±0.89,
P<0.01, 10±1.00 vs. 1.6±0.89, P<0.05). Furthermore, rSulf2‑nu
also showed more lymphatic vessels compared with the
CM-nu group (10±1.00 vs. 6.8±1.48, P<0.05). The results
demonstrated that both exogenous and endogenous Sulf2 from
breast cancer xenografts promoted lymphangiogenesis in nude
mouse ears. Moreover, the effects of purified exogenous Sulf2
on lymphangiogenesis were more pronounced than endogenous Sulf2 (Fig. 6).
Sulf2 promotes lymphangiogenesis in the breast cancer
xenografts. To detect the effect of Sulf2 on lymphangiogenesis
in the breast cancer xenografts, we detected the density of
lymphatic vessels in MDA-MB-231 breast cancer xenografts,
which did not express Sulf2. No significant lymphatic vessels
were detected inside or around the xenografts in control-3.
More lymphatic vessels around the xenografts were detected
in the CM-scid and rSulf2-scid groups (Fig. 7). The results
further certified that Sulf2 increased lymphangiogenesis in

ONCOLOGY REPORTS 36: 3161-3171, 2016

3169

Figure 7. Sulfatase 2 (Sulf2) promotes lymphangiogenesis in the breast cancer xenografts. The images show lymphatic vessels in the breast cancer xenografts,
which are marked by red arrows. No lymphatic vessels were detected inside or around the xenografts in control-3. Conditioned medium (CM)-scid and
recombinant Sulf2 (rSulf2)-scid groups showed more lymphatic vessels around the xenografts.

Figure 8. Change in gene expression caused by Sulfatase 2 (Sulf2) with/without vascular endothelial growth factor-D (VEGF-D) treatment. (A) Gene expression change in lymphatic endothelial cells (LECs) verified by qRT-PCR. (B) The AKT1 protein expression and phosphorylation were affected by Sulf2 and
VEGF-D treatment. *P<0.05, **P<0.01.

breast cancer xenografts and that breast cancer cells secreted
Sulf2 to promote lymphangiogenesis.
Sulf 2 regulates signaling pathway molecular interactions in LECs. Messenger RNA levels of a panel of VEGF
signaling pathway genes were first analyzed by PCR

microarray, followed by qRT-PCR and WB analysis verification. Compared with the control-1, the genes significantly
upregulated following treatment with rSulf2 were PLA2G1B
(4.44±0.84 vs. 1.00, P<0.01), PLA2G5 (7.54±1.21 vs. 1.00,
P<0.01) and AKT1 (3.09±0.62 vs. 1.00, P<0.05). The genes
significantly upregulated by VEGF-D were PLA2G2D
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(2.67±0.14 vs. 1.00, P<0.01), AKT1 (2.85±0.04 vs. 1.00, P<0.01)
and PI3KR1 (1.76±0.06 vs. 1.00, P<0.05). The genes downregulated were PLA2G1B (0.49±0.36 vs. 1.00, P<0.05) and
PI3KR3 (0.57±0.21 vs. 1.00, P<0.05). The genes significantly
upregulated in the rSulf2+VEGF-D group were PLA2G5
(4.84±0.12 vs. 1.00, P<0.01), PLA2G2D (2.91±0.21 vs. 1.00,
P<0.01), PLA2G6 (2.93±0.04 vs. 1.00, P<0.01), AKT1
(2.59±0.16 vs. 1.00, P<0.01) and PI3KR1 (2.01±0.1 vs. 1.00,
P<0.01) (Fig. 8A). Only AKT1 mRNA showed the same significant trends in the three groups and was chosen for further
WB analysis verification. Furthermore, we tested the AKT1
and the phosphorylated AKT1 protein by WB analysis in the
four groups. Compared with the control-1, the expression and
phosphorylation of AKT1 in the LECs revealed a significant
increase in the other groups (Fig. 8B). The results revealed that
Sulf2 and/or VEGF-D could promote AKT1 expression and
activation in the LECs.
Discussion
Sulf2 has been reported to modify the activities of
heparan‑binding growth factors (VEGF and FGF-1) and
influence the signaling pathways of the corresponding
receptors to facilitate angiogenesis. Uchimura et al (5)
validated Sulf2 as a new molecule involved in angiogenesis
through the activation of VEGF and FGF-1. Skobe et al (19) and
Cherng et al (26) certified that the VEGF family is comprised
of different monomeric forms including VEGF145, VEGF165
and VEGF189 and VEGF206. These different monomeric
forms had similar heparan-binding regions, which could be
regulated by Sulf2. VEGF-D is one member of the VEGF
family and also shares similar structures. Harris et al (27)
reported that VEGF-D is an angiogenic and lymphangiogenic
glycoprotein. Heparan-binding regions in VEGF-D were found
within the N- and C-terminal propeptides, which suggested
that VEGF-D could also bind to heparan. The C-terminal
propeptide significantly enhanced this interaction through
the removal of this propeptide from full-length VEGF-D. The
removal of either the N- or C-terminal propeptide was required
for VEGF-D binding to VEGFR-2/VEGFR-3 and formation of
heterodimers, which have recently been shown to positively
regulate angiogenic and lymphangiogenic sprouting (28,29). In
contrast, the removal of both propeptides was required for high
rates of lymph node metastasis. It was also reported that the
propeptides profoundly influenced the molecular interactions
of VEGF-D with VEGFR-3, and these propeptide structures
also promoted the effects of VEGF-D on tumor development.
In our previous study, we demonstrated that Sulf2 was
upstream of VEGF-D and upregulated VEGF-D expression
in breast cancer cells (6). In this study, we studied the role of
Sulf2 in lymphangiogenesis and the mechanism involved in
its function. MCF-7 breast cancer cells released a high level
of Sulf2 protein into the culture medium, which was demonstrated in our previous study (6). In this study, we collected the
CM from the supernatant of MCF-7 cells to study the effect
of endogenous Sulf2 on lymphangiogenesis in breast cancer
cells. We also combined and purified exogenous rSulf2 to
study the direct function and mechanism of Sulf2 in lymphangiogenesis. We found that Sulf2 significantly increased LEC
mobility and lymphatic tube‑like structure formation, inhibited

cisplatin‑induced LEC apoptosis in vitro, but had no direct
effect on cell proliferation and the cell cycle. Moreover, rSulf2
together with VEGF-D, further promoted the proliferation, cell
cycle progression, mobility and tube formation in LECs, while
at the same time inhibited cisplatin-induced apoptosis, especially in the late stage. Sulf2 also significantly improved the
densities of lymphatic vessels in mouse ears and breast cancer
xenografts in vivo. These results showed that Sulf2 not only
enhanced VEGF-D expression, but also enhanced the activity
of VEGF-D. Furthermore, we found that the signaling pathway
gene AKT1 was upregulated and activated by Sulf2.
In summary, Sulf2 markedly promoted lymphangiogenesis
in breast cancer, possibly by promoting VEGF-D expression
and by activating the AKT1-related signaling pathway. This
finding confirmed the role of Sulf2 as a biomarker of breast
cancer progression. More importantly, new therapeutic
approaches targeting Sulf2 could improve the clinical
outcomes in patients with lymph node-positive breast cancer.
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